2型糖尿病并发周围神经病理性疼痛的患病率及危险因素分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (732 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the incidence and risk factors of diabetic peripheral neuropathic pain (DPNP) among inpatients with type 2 diabetes. Methods Two hundred and sixty patients with type 2 diabetic peripheral neuropathy were selected, and the basic information and laboratory data on these patients were collected. According to the Leeds Assessment of Neuropathic Symptoms and Signs(LANSS)questionnaire, a score ≥12 was diagnosed as DPNP, while a score of less than 12 was classified as non-DPNP. Patients were divided into the DPNP group (n=129) and non-DPNP group(n=131). The related data was compared between the two groups, and the significant variables between the groups were included in the binary logistic regression analysis. Statistical analysis showed that the course of disease, diabetic nephropathy, HbA₁c, low HDL-C, and UACR were risk factors for DPNP. Results There was statistically significant difference between the two groups in the course of disease and the incidence of complications with diabetic retinopathy and diabetic nephropathy (all P＜0.05), but not in gender, age, BMI, smoking history, drinking history, family history of disease, levels of education, complications with hypertension and cardiovascular diseases, medication, blood glucose monitoring, treatment plans, weight control, diet control or physical activity (all P＞0.05). Levels of HbA₁c, HDL-C, urinary microalbumin and UACR were statistically different between the two groups (all P＜0.05), but those of fasting blood glucose and C peptide, 2 h postprandial blood glucose and C peptide, triglycerides, total cholesterol, LDL-C, urea, creatinine, uric acid and urine creatinine were not (all P＞0.05). Binary Logistic regression analysis showed that the course of disease (OR=1.042, 95%CI 1.001-1.085, P=0.045), diabetic nephropathy (OR=3.565, 95%CI 1.497-8.487, P=0.004), HbA₁c (OR=1.179, 95%CI 1.041-1.334, P=0.009), HDL-C (OR=0.228, 95%CI 0.073-0.705, P=0.010)and UACR (OR=1.004, 95%CI 1.001-1.008, P=0.027) were risk factors for DPNP. Conclusions Patients with a longer clinical course, diabetic nephropathy, increased HbA₁c, decreased HDL-C, and increased UACR are at high risk of diabetic peripheral neuropathic pain.

Key words： type 2 diabetes mellitus diabetic peripheral neuropathic pain incidence risk factors

Received: 01 February 2021

ZTFLH:

R614

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Huifang
	WEI Biyu
	GAO Minglong

Cite this article:

YANG Huifang,WEI Biyu,GAO Minglong. Incidence and risk factors of type 2 diabetes complicated by peripheral neuropathic pain among inpatients[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(7): 562-567.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2021/V32/I7/562

[1]	Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy[J].Clin Ther, 2018, 40(6): 828-849.
[2]	Tesfaye S, Boulton A J, Dyck P J, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments[J] .Diabetes Care, 2010, 33(10): 2285-2293.
[3]	Bohlega S, Alsaadi T, Amir A,et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the Middle East region[J]. J Int Med Res,2010,38(2):295-317.
[4]	Busui R, Boulton A J, Feldman E L, et al. Diabetic neuropathy: a position statement by the American diabetes association[J].Diabetes Care, 2017, 40(1): 136-154.
[5]	Vileikyte L,Peyrot M,Gonzalez J S,et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study[J].Diabetologia, 2009, 52(7): 1265-1273.
[6]	Sadosky A, Schaefer C, Mann R,et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey[J].Diabetes Metab Syndr Obes, 2013, 6: 79-92.
[7]	Ziegler D, Landgraf R, Lobmann R, et al. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (protect study)[J]. Diabetes Res Clin Pract,2018,139(2): 147-154.
[8]	Abbott C A, Malik R A, Ross E R, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK[J]. Diabetes Care, 2011, 34(10):2220-2224.
[9]	Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study[J]. PLoS One, 2013, 8(9): e74195.
[10]	Liu Xiuxiu, Xu Yuyan, An Miaomiao,et al. The risk factors for diabetic peripheral neuropathy: a meta-analysis[J] .PLoS One, 2019, 14(2): e0212574.
[11]	Unal C I,Sarioglu A S,Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4[J].J Pain, 2010, 11(11): 1129-1135.
[12]	Ponirakis G,Elhadd T,Chinnaiyan S,et al. Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar[J].J Diabetes Investig, 2019,10(6) : 1556-1564.
[13]	Rosenberger D C,Blechschmidt V,Timmerman H,et al. Challenges of neuropathic pain: focus on diabetic neuropathy[J] .J Neural Transm, 2020, 127(26): 589-624.
[14]	Acker K, Bouhassira D, Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics[J]. Diabetes Metab,2009, 35(3): 206-213.
[15]	Jambart S, Ammache Z, Haddad F, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region[J]. J Int Med Res,2011, 39(2): 366-377.
[16]	Halawa M R, Karawagh A, Zeidan A, et al. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia[J]. Curr Med Res Opin,2010, 26(2): 337-343.
[17]	Cole B E. Diabetic peripheral neuropathic pain: recognition and management[J]. Pain Med, 2007,8:S27-32.
[18]	Huang C,Chen T,Weng M, et al. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients[J] .Kaohsiung J Med Sci, 2005, 21(1): 15-21.
[19]	Alkhatatbeh M, Razzak K K. Neuropathic pain is not associated with serum vitamin D but is associated with female gender in patients with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2019, 7(1):e000690.
[20]	Tesfaye S,Vileikyte L,Rayman G,et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management[J] .Diabetes Metab Res Rev, 2011, 27(7): 629-638.
[21]	Weng Y,Tsai S,Lyu R,et al. Diabetic distal symmetrical polyneuropathy: correlation of clinical, laboratory, and electrophysiologic studies in patients with type 2 diabetes mellitus[J] .J Diabetes Res, 2020,(28):6356459.
[22]	John D, Thomas L E, Szuhuei W,et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy[J] .J Clin Endocrinol Metab, 2009, 94(6): 2157-2163.
[23]	Bansal D, Gudala K, Muthyala H, et al. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting[J]. J Diabetes Investig, 2014 ,5(6):714-721.
[24]	Kamenov Z A, Parapunova R A, Georgieva R T. Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus[J].Gend Med,2010, 7(6):600-615.
[25]	Ziegler D, Landgraf R, Lobmann R, et al.Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (protect study)[J].Diabetes Res Clin Pract,2018, 139(5): 147-154.
[26]	Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes[J]. Can J Diabetes 2015, 39(4):285-295.
[27]	Amato C,Morganti R,Greco C,et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities[J].Diab Vasc Dis Res, 2016, 13(6): 418-428.
[28]	Pai Y,Lin C,Lee I,et al. Prevalence and biochemical risk factors of diabetic peripheral neuropathy with or without neuropathic pain in Taiwanese adults with type 2 diabetes mellitus[J] .Diabetes Metab Syndr, 2018, 12(2): 111-116.